News | Published:

Markers of dispute

Nature Medicine volume 15, pages 13391343 (2009) | Download Citation

Subjects

The gold standard for early detection of prostate cancer, PSA, has recently come under fire for its high rate of false positives. Virginia Hughes investigates some of the researchers hunting for better alternatives and asks whether their promises of creating viable—and profitable—biomarker tests will ever be realized.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. N. Engl. J. Med. 317, 909–916 (1987).

  2. 2.

    et al. Cancer Res. 51, 6514–6520 (1991).

  3. 3.

    et al. Urology 69, 714–720 (2007).

  4. 4.

    The Washington Post 26 April 2007, A3.

  5. 5.

    Newsweek <> (26 April 2007).

  6. 6.

    et al. Ann. Intern. Med. 119, 914–923 (1993).

  7. 7.

    et al. Cancer 80, 1852–1856 (1997).

  8. 8.

    et al. N. Engl. J. Med. 360, 1310–1319 (2009).

  9. 9.

    et al. N. Engl. J. Med. 360, 1320–1328 (2009).

  10. 10.

    et al. J. Am. Med. Assoc. 302, 1685–1692 (2009).

  11. 11.

    Clin. Biochem. 40, 1437–1439 (2007).

  12. 12.

    et al. Clin. Cancer Res. 14, 3785–3791 (2008).

Download references

Author information

Affiliations

  1. Virginia Hughes is a freelance journalist based in Brooklyn, New York.

    • Virginia Hughes

Authors

  1. Search for Virginia Hughes in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm1209-1339

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing